Informace o publikaci

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Autoři

ŠTEFÁNIK Michal VALDES James J. EZEBUO Fortunatus C. HAVIERNIK Jan UZOCHUKWU Ikemefuna C. FOJTÍKOVÁ Martina SALÁT Jiří EYER Luděk RŮŽEK Daniel

Rok publikování 2020
Druh Článek v odborném periodiku
Časopis / Zdroj Microorganisms
Fakulta / Pracoviště MU

Přírodovědecká fakulta

Citace
www https://doi.org/10.3390/microorganisms8040599
Doi http://dx.doi.org/10.3390/microorganisms8040599
Klíčová slova FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral
Popis Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info